Included with registration (non-cme events).


Tuesday, March 2, 1:00-2:00pm (non-CME)

Assessing the risk of Acute Kidney Injury (AKI)- A paradigm shift in renal care
V. Seenu Reddy, MD, MBA, FACS, FACC
Acute Kidney Injury (AKI) is one of the more prevalent and serious morbidities in hospitalized patients and is associated with a multitude of acute and chronic conditions. The economic and public health burden of AKI is significant with substantially increased mortality, morbidity, length of ICU stay and in-hospital costs. The NEPHROCHECK® Test [TIMP-2 • IGFBP-7] is an FDA cleared combination biomarker test that can significantly discriminate AKI from no-AKI, and when used in conjunction with clinical evaluation, can aid physicians in optimizing patient management.

Live Questions and Answers

Wednesday, March 3, 1:00-2:00pm (non-CME)

Citrate utilization in CRRT and the impact of RegioCit Replacement Solution
Ashita Tolwani, MD
Review COVID-19 and the impact of AKI
Anticoagulation in COVID-19
Key differences with Citrate and Heparin
Citrate use with CRRT in the era of COVID-19
Experiences with Regiocit Replacement Solution

Live Questions and Answers

Thursday, March 4, 1:00-2:00pm (non-CME)

Strategies to limit hypophosphatemia in critically ill patients on CRRT
Javier Neyra, MD and Melissa Thompson-Bastin
Phosphate homeostasis during critical illness
Incidence and impact of hypophosphatemia during CRRT
Reactive approaches to manage hypophosphatemia during CRRT –> sliding scales
Preemptive approaches by using phosphate-containing solutions (compounded vs. readily available -Phoxillum)

Live Questions and Answers